
WE CLAIM:

1. A compound represented by Formula Ia:



Ia

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is –O-;

R^1 is C_1-C_6 alkyl, or C_4-C_{20} carbocyclylalkyl;

each of R^4 and R^5 is H;

X^1 is C_1-C_6 alkylene;

D is phenyl substituted with $–L^2$-NR^6R^7;

n is 0;













L^2 is C_1-C_6 alkylene; and


R^6 and R^7 taken together with the nitrogen to which they are attached form an unsubstituted 4-6 membered heterocycle comprising 0 to 2 heteroatoms selected from N, O and S.











2. The compound of Claim 1, wherein X^1 is $–CH_2$-.





3. The compound of Claim 1 or Claim 2, wherein L^2 is $–CH_2$-.

4. A compound of Claim 1 selected from the group consisting of


,

,

,

,

,

,

,

,

,

,

,

,



,

,


,

,

,

,

,

,

,

,

,

,


,

,

, and

;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4, having the structure:


or


or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition for treating a hepatitis B viral infection, comprising a therapeutically effective amount of a compound of any one of Claims 1, 2, 4 and 5 and a pharmaceutically acceptable carrier or excipient.

7. A pharmaceutical composition for treating a hepatitis B viral infection, comprising a therapeutically effective amount of a compound of any one of Claims 1, 2, 4 and 5.

8. The pharmaceutical composition of Claim 7 further comprising an additional therapeutic agent selected from the group consisting of lamivudine, adefovir, tenofovir, telbivudine, entecavir, interferon alpha-2b, pegylated interferon alpha-2a, interferon alpha 2a, interferon alpha N1, prednisone, predinisolone, Thymalfasin®, retinoic acid receptor agonists, 4-methylumbelliferone, Alamifovir®, Metacavir®, Albuferon®, cytokines and agonists of TLRs.